However, the low specificity of PSA in determining the presence of PCa and suboptimal ability to discriminate between clinically significant and indolent cancer may lead to unnecessary prostate biopsies and overtreatment, especially in men presenting with a total PSA level of < 10 ng/mL1,2. This evidence concerns the gene KLK3 and cancer.